Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion type Assertion NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_head.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion description "[A striking example of management differences pertains to BRCA1 and BRCA2 mutation-positive breast cancers wherein those with BRCA1 mutations are frequently estrogen receptor (ER)-negative in contrast to BRCA2 mutations which are more frequently ER-positive; therein, significant differences exist with respect to anti-estrogen therapy which will be more amenable to BRCA2 versus BRCA1 mutation carriers manifesting breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_provenance.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion evidence source_evidence_literature NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_provenance.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion SIO_000772 18086271 NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_provenance.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion wasDerivedFrom befree-2016 NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_provenance.
- NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_assertion wasGeneratedBy ECO_0000203 NP645679.RAYqF2zAnGP8V8JYTEcuUrJBqNpGTJEqbvYDyKofKhd74130_provenance.